|
KMID : 1009020100080010026
|
|
Clinical Psychopharmacology and Neuroscience
2010 Volume.8 No. 1 p.26 ~ p.29
|
|
|
Effects of Cilostazol on Cognitive Deficits in Mice after Repeated Administration of Phencyclidine
|
|
Hashimoto Kenji
Fujita Yuko
Ishima Tamaki
Horio Mao
Hagiwara Hiroko
Tanibuchi Yuko
Iyo Masaomi
|
|
|
Abstract
|
|
|
Objective: To examine the effects of cilostazol, a selective inhibitor of type III phosphodiesterase (PDE), on cognitive deficits in mice after repeated administration of the N-methyl-D-aspartate (NMDA) receptor antagonist phencyclidine (PCP).
Methods: Saline (10 ml/kg/day) or PCP (10 mg/kg/day) were administered subcutaneously to mice for 10 days (once daily on days 1?5 and 8?12). Three days (day 15) after the final administration of saline or PCP, vehicle (0.5% carboxymethylcellulose) or cilostazol (0.3, 3, 10 or 30 mg/kg/day) were administered orally for 14 consecutive days (once daily on days 15?28). The novel object recognition test (NORT) was performed 24 hours (day 29) after the final administration.
Results: In the NORT, PCP -induced cognitive deficits in mice were improved significantly by subsequent sub-chronic (14 days) administration of cilostazol (3, 10 or 30 mg/kg/day), but not by the lowest dose of cilostazol (0.3 mg/kg/day).
Conclusion: This study suggests that cilostazol ameliorates PCP-induced cognitive deficits in mice. Therefore, it is likely that cilostazol has therapeutic potential for cognitive deficits in schizophrenia.
|
|
|
KEYWORD
|
|
|
Schizophrenia, NMDA receptor, Phencyclidine, Cognition, Cilostazol
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|